All CompaniesBiological Products, (No Diagnostic Substances)
GILD
Gilead Sciences Inc$132.73updated Jul 30, 2026
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Total Trades
14
Politicians Trading
8
Last Traded
May 6, 2026
Price history
Congressional Trades
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Jared MoskowitzD | Jun 19, 2026 | May 6, 2026 | Buy | $1,001 - $15,000 | -2.62% |
| Jared MoskowitzD | Jun 19, 2026 | May 6, 2026 | Buy | $1,001 - $15,000 | -2.62% |
| Alan ArmstrongR | Jul 21, 2026 | Mar 27, 2026 | Buy | $1,001 - $15,000 | -1.13% |
| Josh GottheimerD | Feb 26, 2026 | Jan 27, 2026 | Buy | $1,001 - $15,000 | -5.85% |
| Val T. HoyleD | Oct 10, 2025 | Sep 23, 2025 | Sell | $1,001 - $15,000 | +16.02% |
| Marjorie Taylor GreeneR | Jun 18, 2025 | Jun 6, 2025 | Buy | $1,001 - $15,000 | +18.02% |
| Josh GottheimerD | Jun 11, 2025 | May 14, 2025 | Sell | $1,001 - $15,000 | +34.92% |
| Jefferson ShreveR | Jun 22, 2025 | May 12, 2025 | Sell | $15,001 - $50,000 | +27.85% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +29.10% |
| Marjorie Taylor GreeneR | May 6, 2025 | May 5, 2025 | Buy | $1,001 - $15,000 | +29.10% |
| John BoozmanR | May 14, 2025 | Apr 16, 2025 | Sell | $1,001 - $15,000 | +26.55% |
| Jefferson ShreveR | Apr 11, 2025 | Mar 31, 2025 | Buy | $15,001 - $50,000 | +18.46% |
| Carol D. MillerR | Apr 11, 2025 | Mar 10, 2025 | Buy | $1,001 - $15,000 | +13.24% |
| Josh GottheimerD | Apr 10, 2025 | Mar 7, 2025 | Buy | $1,001 - $15,000 | +13.05% |